{"nctId":"NCT02054897","briefTitle":"Efficacy and Safety of Semaglutide Once-weekly Versus Placebo in Drug-na√Øve Subjects With Type 2 Diabetes","startDateStruct":{"date":"2014-02-03","type":"ACTUAL"},"conditions":["Diabetes","Diabetes Mellitus, Type 2"],"count":388,"armGroups":[{"label":"Semaglutide 1.0 mg","type":"EXPERIMENTAL","interventionNames":["Drug: semaglutide"]},{"label":"Semaglutide 0.5 mg","type":"EXPERIMENTAL","interventionNames":["Drug: semaglutide"]},{"label":"Semaglutide placebo 1.0 mg","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: placebo"]},{"label":"Semaglutide placebo 0.5 mg","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: placebo"]}],"interventions":[{"name":"semaglutide","otherNames":[]},{"name":"placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria: - For Japan only: Male or female, age above or equal to 20 years at the time of signing inform consent - Subjects diagnosed with type 2 diabetes and treated with diet and exercise for at least 30 days before screening - HbA1c 7.0 - 10.0 % (53 - 86 mmol/mol) (both inclusive) Exclusion Criteria: - Female who is pregnant, breast-feeding or intends to become pregnant or is of child-bearing potential and not using adequate contraceptive method (adequate contraceptive measures as required by local regulation or practice) throughout the trial including the 5 week follow-up period. United Kingdom: Adequate contraceptive measures are defined as established use of oral, injected or implanted hormonal methods of contraception, placement of an intrauterine device or intrauterine system, barrier methods of contraception (condom or occlusive cap with spermicidal foam/gel/film/cream/suppository), male sterilisation (where partner is sole partner of subject), or true abstinence (when in line with preferred and usual lifestyle) - Any chronic disorder or severe disease which, in the opinion of the investigator, might jeopardise subject's safety or compliance with the protocol - Treatment with any glucose lowering agent(s) in a period of 90 days prior to screening. An exception is short-term treatment (no longer than 7 days in total) with insulin in connection with inter-current illness - History of chronic or idiopathic acute pancreatitis - Screening calcitonin value above or equal to 50 ng/L (pg/mL) - Personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 (MEN 2) - Impaired renal function defined as eGFR (estimated glomerular filtration rate ) below 30 mL/min/1.73 m\\^2 per modification of diet in renal disease (MDRD) formula (4 variable version) - Acute coronary or cerebrovascular event within 90 days before randomisation - Heart failure, New York Heart Association class IV","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change in HbA1c (Glycosylated Haemoglobin)","description":"Change from baseline (week 0) in HbA1c was evaluated after 30 weeks of treatment. Missing data were imputed from a mixed model for repeated measurements with treatment and country as fixed factors and baseline value as covariate, all nested within visit.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.47","spread":"1.02"},{"groupId":"OG001","value":"-1.56","spread":"1.26"},{"groupId":"OG002","value":"-0.00","spread":"0.90"}]}]}]},{"type":"SECONDARY","title":"Change in Body Weight","description":"Change from baseline (week 0) in body weight was evaluated after 30 weeks of treatment. Missing data were imputed from a mixed model for repeated measurements with treatment and country as fixed factors and baseline value as covariate, all nested within visit.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.68","spread":"4.03"},{"groupId":"OG001","value":"-4.67","spread":"5.19"},{"groupId":"OG002","value":"-0.89","spread":"3.46"}]}]}]},{"type":"SECONDARY","title":"Change in Fasting Plasma Glucose (FPG)","description":"Change from baseline (week 0) in FPG was evaluated after 30 weeks of treatment. Missing data were imputed from a mixed model for repeated measurements with treatment and country as fixed factors and baseline value as covariate, all nested within visit.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.41","spread":"2.55"},{"groupId":"OG001","value":"-2.39","spread":"2.74"},{"groupId":"OG002","value":"-0.55","spread":"2.2"}]}]}]},{"type":"SECONDARY","title":"Change in Systolic and Diastolic Blood Pressure","description":"Change from baseline (week 0) in systolic and diastolic blood pressure was evaluated after 30 weeks of treatment. Missing data were imputed from a mixed model for repeated measurements with treatment and country as fixed factors and baseline value as covariate, all nested within visit.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.29","spread":"12.58"},{"groupId":"OG001","value":"-2.74","spread":"11.58"},{"groupId":"OG002","value":"-2.01","spread":"11.23"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.73","spread":"6.88"},{"groupId":"OG001","value":"0.22","spread":"7.6"},{"groupId":"OG002","value":"0.60","spread":"7.59"}]}]}]},{"type":"SECONDARY","title":"Subjects Who Achieve (Yes/no):HbA1c Below 7.0% (53 mmol/Mol) American Diabetes Association Target","description":"Percentage of subjects who achieve (yes/no): HbA1c below 7.0% (53 mmol/mol) American Diabetes Association target after 30 weeks' treatment. Missing HbA1c data imputed from a mixed model for repeated measurements with treatment and country as fixed factors and baseline value as covariate, all nested within visit.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"74.2","spread":null},{"groupId":"OG001","value":"72.3","spread":null},{"groupId":"OG002","value":"24.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"25.8","spread":null},{"groupId":"OG001","value":"27.7","spread":null},{"groupId":"OG002","value":"75.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Subjects Who Achieve (Yes/no):HbA1c Below or Equal to 6.5% (48 mmol/Mol) American Association of Clinical Endocrinologists Target","description":"Percentage of subjects who achieve (yes/no): HbA1c below 6.5% (48 mmol/mol) American Diabetes Association target after 30 weeks' treatment. Missing HbA1c data imputed from a mixed model for repeated measurements with treatment and country as fixed factors and baseline value as covariate, all nested within visit.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"59.4","spread":null},{"groupId":"OG001","value":"60.0","spread":null},{"groupId":"OG002","value":"13.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"40.6","spread":null},{"groupId":"OG001","value":"40.0","spread":null},{"groupId":"OG002","value":"86.8","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":7,"n":128},"commonTop":["Nausea","Diarrhoea","Headache","Nasopharyngitis","Lipase increased"]}}}